Moderna: Maintaining Sell Despite Consolidation - And Why MRNY Won't Help Either

Group 1 - The analyst had a sell call on Moderna (MRNA) in April 2025, which was considered bold at the time due to the significant correction and perception of limited further downside [1] - The analyst has over 20 years of experience in quantitative research, financial modeling, and risk management, focusing on equity valuation, market trends, and portfolio optimization [1] - The analyst previously served as Vice President at Barclays, leading teams in model validation, stress testing, and regulatory finance, indicating a strong background in both fundamental and technical analysis [1] Group 2 - The analyst collaborates with a research partner, who is also their spouse, to co-author investment research, combining complementary strengths for high-quality insights [1] - The research approach emphasizes rigorous risk management and a long-term perspective on value creation, with a focus on macroeconomic trends, corporate earnings, and financial statement analysis [1] - The goal is to provide actionable ideas for investors aiming to outperform the market [1]